Values as of: 2024-12-27
COMMON STOCK | Health Information Services |
Last Closing
USD 10.69Change
-0.16 (-1.47)%Market Cap
USD 1.75BVolume
0.88MAnalyst Target
N/AVerdict
Verdict
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Company Website : https://www.certara.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| GEHC | GE HealthCare Technologies Inc.. |
-0.20 (-0.25%) |
USD 37.81B |
| HQY | HealthEquity Inc |
-1.11 (-1.14%) |
USD 8.82B |
| TEM | Tempus AI, Inc. Class A Common.. |
-0.17 (-0.48%) |
USD 7.92B |
| WAY | Waystar Holding Corp. Common S.. |
-0.25 (-0.65%) |
USD 4.47B |
| BTSG | BrightSpring Health Services, .. |
-0.58 (-3.30%) |
USD 3.18B |
| PRVA | Privia Health Group Inc |
-0.31 (-1.54%) |
USD 2.52B |
| OMCL | Omnicell Inc |
-0.52 (-1.17%) |
USD 2.13B |
| PINC | Premier Inc |
+0.05 (+0.23%) |
USD 2.08B |
| WGS | GeneDx Holdings Corp. |
-1.40 (-1.76%) |
USD 2.03B |
| GDRX | Goodrx Holdings Inc |
+0.10 (+2.21%) |
USD 1.87B |
N/A
| Market Performance vs. Industry/Classification (Health Information Services) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -39.23% | 38% | F | 22% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -39.23% | 38% | F | 22% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -39.23% | 38% | F | 22% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -39.23% | 38% | F | 22% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -15.02% | 39% | F | 16% | F | ||
| Dividend Return | -15.02% | 37% | F | 16% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 19.20% | 95% | A | 78% | C+ | ||
| Risk Adjusted Return | -78.24% | 17% | F | 8% | B- | ||
| Market Capitalization | 1.75B | 77% | C+ | 77% | C+ | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median revenue growth in the previous 5 years compared to its sector
